Oxford BioDynamics (GB:OBD) has released an update.
Oxford BioDynamics’ EpiSwitch Prostate Screening (PSE) test is set to be used in a five-year National Cancer Institute clinical trial for monitoring biochemically recurrent prostate cancer. This trial aims to identify early markers of cancer progression using various techniques, including the PSE test, with around 250 patients undergoing regular monitoring. The collaboration highlights the quick recognition of the PSE test’s potential in cancer monitoring by prominent research institutions.
For further insights into GB:OBD stock, check out TipRanks’ Stock Analysis page.
